ライフサイエンスコーパス: untreated group

1 PNU-120596 (treated group) or vehicle only (untreated group).

2 atients with RA or RAEB (160.2% +/- 90.5% of untreated group).

3 le progression pathways in the 4-NQO vs. the untreated group.

4 rom the lungs in both groups and asci in the untreated group.

5 ctively, compared with 45.5 d in the control untreated group.

6 ify gut tracer retention with respect to the untreated group.

7 eated-XO groups, and 3.2% in the ranibizumab untreated group.

8 nd visual fields (P = 0.005), compared to an untreated group.

9 ased significantly compared to those for the untreated group.

10 3 +/- 0.011%, p < 0.0001) was lower than the untreated group.

11 istically significant when compared with the untreated group.

12 mals was significantly less than that in the untreated group.

13 he DZ-treated injury group compared with the untreated group.

14 isease-treated group compared to the disease-untreated group.

15 eduction of IL-5 was observed in the SLIT or untreated group.

16 P<0.0001), with no significant change in the untreated group.

17 nhibitor of NOS-2, and compared them with an untreated group.

18 similar during repeated measurements in the untreated group.

19 ibition) relative to vessels in the control, untreated group.

20 ally labeled 131I-RS11 group and none in the untreated group.

21 ified differences between EBOTAb-treated and untreated groups.

22 n the composite score between the treated vs untreated groups.

23 t rates between infants from the treated and untreated groups.

24 ooled ranibizumab treated-XO and ranibizumab untreated groups.

25 analysis was performed to match treated and untreated groups.

26 ed to balance covariates between treated and untreated groups.

27 es were compared between the treated and the untreated groups.

28 the caudal cord, a phenomenon not present in untreated groups.

29 pth (P = 0.033) compared to root planing and untreated groups.

30 njury was equally severe in both treated and untreated groups.

31 to treated (partial spectacle correction) or untreated groups.

32 ly reduced villus height in both U74389F and untreated groups.

33 significant differences between treated and untreated groups.

34 val over an 18-week period compared with the untreated group (100% versus 50%).

35 in the presence of TRAIL (63.0% +/- 10.4% of untreated group [100%]), numbers increased in patients w

36 to-media ratio with CFVs: 0.89+/-0.14 in the untreated group 2 versus 0.11+/-0.04 in the control grou

37 d Kd was higher (lower affinity) than in the untreated group (6.5+/-1.4, p<0.05).

38 ct AEs were less frequent in the ranibizumab untreated group: 6.3% versus 12.5% and 12.1% in the rani

39 d) patients (1 [4%] of 28 patients) than the untreated group (8 [22%] of 37 patients) in this populat

40 he CT-1-treated group was higher than in the untreated group and prevented IRI-induced reduction in t

41 9% was achieved for 36.2% of predictions for untreated groups and 6.2% for treated groups.

42 ended survival time (> 2.5 times that of the untreated group) and histologic signs of radiation-induc

43 ally higher in the treated compared with the untreated group, and this trend was sustained throughout

44 isease (clinical index of 1.6 +/- 0.5 in the untreated group as compared with 0.0 +/- 0.0 for the tre

45 isease (clinical index of 4.3 +/- 0.7 in the untreated group as compared with 0.5 +/- 0.3 for the tre

46 I, 20-205 cells/ microL]), compared with the untreated group at 24 weeks.

47 ues for the acute treatment group versus the untreated group at 72 weeks without therapy were as foll

48 n the following groups of rats: (a) control, untreated group, (b) MK-801-treated groups (0.03 to 1.0

49 In untreated groups, bcl-2 mRNA decreased significantly ove

50 ower HIV RNA levels at 24 weeks than did the untreated group, but differences were no longer apparent

51 s estimated by comparing between treated and untreated groups by using Cox proportional hazards model

52 and factor XII were decreased in the disease-untreated group compared to the C11C1 disease-treated gr

53 ortion of persons who died was higher in the untreated group compared with either treatment group (Pr

54 indings showed increased liver damage in the untreated group compared with PY.

55 spite these baseline imbalances, treated and untreated groups did not differ in progression to Oxford

56 The treated and untreated groups did not differ in time to an OHS score

57 groups were compared with those noted in the untreated group during the same periods of observation a

58 he phentermine/fenfluramine group, while the untreated group had no anorexigen use during the previou

59 were seen in the E2F-decoy group than in the untreated group (hazard ratio 0.34 [95% CI 0.12-0.99]).

60 Rats with NAFLD were untreated (group II, MSG-obesity group) and treated with

61 ute rejection was similar in the treated and untreated groups in both the prophylaxis (12% vs. 21%; P

62 th normal IOP, eyes with elevated IOP in the untreated group lost 36% of their retinal ganglion cells

63 ated slower MF progression compared with the untreated group (mean [SD] increase of 3.1% [7.4%] vs 10

64 not receive these prescriptions were in the untreated group (n = 1011).

65 In the untreated group (n = 112), 59% of patients with a PgR-po

66 nd exposures, respectively) compared with an untreated group (n = 8).

67 In the untreated group (n = 9), baseline cortical blood flow (3

68 Untreated groups (n = 8 to 9 per group) were compared (a

69 An untreated group of 10 rats manifesting chronic rejection

70 All treated and untreated groups of amoebae from the 2 strains exhibited

71 sets were randomly assigned to 'treated' or 'untreated' groups of increasing size and voxel-wise incr

72 nequally distributed between the treated and untreated groups or increased mortality by at least 50%.

73 e and 63 +/- 20 mL/min at 120 minutes in the untreated group (p = 0.0001).

74 R, 3.34; 95% CI, 2.09-5.35), and 4.1% in the untreated group (P<.001).

75 tgrowth versus 5 of 12 (42%) patients in the untreated group (P=0.05).

76 bitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the sam

77 rences were found between statin-treated and untreated groups regarding rescue therapy intensity or 1

78 ial, ranibizumab treated-XO, and ranibizumab untreated groups, respectively.

79 The untreated group showed 49% v 57% 10-year recurrence-free

80 In the untreated group, staining for ER and PR colocalized with

81 .005; 35% in aged, P <.05) compared with the untreated groups that amounted to more than 1 billion ad

82 In the untreated group, the basophil response remained comparab

83 Unlike the patients in the untreated group, the patients in the treated group mount

84 Compared to the untreated group, treatment with adenosine (7.2 mg/kg) in

85 ination, the mean survival time (MST) of the untreated group was 5.2 +/- 0.8 days.

86 period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confi

87 ginterferon alfa-2a group and 6 (19%) in the untreated group were withdrawn prematurely.

88 ginterferon alfa-2a group and 9 (32%) in the untreated group were withdrawn prematurely; whereas in t

89 45 (54%) of the deaths, even in the untreated group, were associated with immaturity.

90 T-kininogen was increased in the disease-untreated group when compared with the C11C1 disease-tre

91 tuzumab and in 20 patients from a previously untreated group who received similar doses subcutaneousl

92 imals treated with soluble receptors and the untreated group with respect to recruitment of inflammat

93 erson-years [95% CI, 0.10 to 0.91]) than the untreated groups with mild to moderate OSA (0.94 per 100

94 losartan-treated (100 mg/L drinking H2O) and untreated groups, with lean Zucker rats as controls.

95 Rejection occurred in the untreated group within 7 days.